In our opinion, the present results, especially the upregulating effect of miR-34a on the expression level of α-SMA in A549 cells, would lead to concerns regarding the clinical use of miR-34a preparations in p53-positive tumor cells. This evidence concerns the gene ACTA1 and neoplasm.